Trial
NCT02203578
Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease
UnknownTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Rutgers, The State University of New Jersey
Collaborators
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey
Condition
Graft Versus Host Disease
Intervention
romidepsin
Why stopped
slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-30